Albumin dialysis MARS: Knowledge from 10 years of clinical investigation

ASAIO Journal

Volumn 55, Issue 5, 2009, Pages 498-502

  Mitzner, Steffen R ^a   Stange, Jan ^a   Klammt, Sebastian ^a   Koball, Sebastian ^a   Hickstein, Heiko ^a   Reisinger, Emil C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LIVER FAILURE; ANTI-COAGULATION; BINDING CAPACITIES; CHRONIC LIVER DISEASE; CLINICAL INVESTIGATION; CLINICAL STUDY; COMMON STANDARDS; KIDNEY FUNCTION; LIVER FAILURE; LIVER REGENERATION; LIVER TRANSPLANTATION; PATHOPHYSIOLOGICAL; RECIRCULATING SYSTEM; TECHNICAL PROCESS; THERAPEUTIC TOOLS;

ADSORPTION; DETOXIFICATION; DIALYSIS; PATIENT TREATMENT; POLYSACCHARIDES;

LIVER;

ALBUMIN; HEPARIN; TOXIN;

ALBUMIN DIALYSIS; ARTICLE; BINDING AFFINITY; BRAIN EDEMA; BRAIN FUNCTION; DRUG INTOXICATION; DRUG OVERDOSE; HEMODYNAMICS; HEPARINIZATION; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER REGENERATION; LIVER TRANSPLANTATION; PATIENT SAFETY; PATIENT SELECTION; PROTEIN BINDING; SURVIVAL TIME;

ALBUMINS; ANIMALS; CLINICAL TRIALS AS TOPIC; DIALYSIS; HUMANS; LIVER FAILURE; MEMBRANES, ARTIFICIAL;

EID: 70349095559     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3181b37d86     Document Type: Article

References (62)

1. Ho DW, Fan ST, To J, et al.: Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model. Gut 50: 869-876, 2002.
2. Ash SR, Carr DJ, Sullivan TA: Sorbent suspension reactor for extracorporeal detoxification in hepatic failure or drug overdose. ASAIO J 50: lviii-lxv, 2004.
3. Vienken J, Christmann H: How can liver toxins be removed? Filtration and adsorption with the Prometheus system. Ther Apher Dial 10: 125-131, 2006.
4. Mitzner S, Klammt S, Stange J, Schmidt R: Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 10: 108-117, 2006.
5. Mitzner SR, Stange J, Klammt S, et al.: Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 12: S75-S82, 2001.
6. Nadalin S, Heuer M, Wallot M, et al.: Paediatric acute liver failure and transplantation: The University of Essen experience. Transpl Int 20: 519-527, 2007.
7. Yuan JZ, Ye QF, Zhao LL, et al.: Preoperative risk factor analysis in orthotopic liver transplantation with pretransplant artificial liver support therapy. World J Gastroenterol 12: 5055-5059, 2006.
8. Gaspari R, Avolio AW, Zileri Dal Verme L, et al.: Molecular adsorbent recirculating system in liver transplantation: Safety and efficacy. Transplant Proc 38: 3544-3551, 2006.
9. Chiu A, Chan LM, Fan ST: Molecular adsorbent recirculating system treatment for patients with liver failure: The Hong Kong experience. Liver Int 26: 695-702, 2006.
10. Stefoni S, Colì L, Bolondi L, et al.: Molecular adsorbent recirculating system (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients. Int J Artif Organs 29: 207-218, 2006.
11. Novelli G, Rossi M, Pretagostini M, et al.: One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 37: 2557-2559, 2005.
12. Heemann U, Treichel U, Loock J, et al.: Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology 36: 949-958, 2002.
13. Di Campli C, Santoro MC, Gaspari R, et al.: Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc 37: 2547-2550, 2005.
14. Mitzner S, Stange J, Dillmann A, et al.: Removal of protein-bound uremic toxins by albumin dialysis: In vivo results. Nephrol Dial Transplant 14: A201, 1999.
15. Guo LM, Liu JY, Xu DZ, et al.: Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 23: 16-20, 2003.
16. Sen S, Davies NA, Mookerjee RP, et al.: Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl 10: 1109-1119, 2004.
17. Kurtovic J, Boyle M, Bihari D, Riordan SM: Nitric-oxide-lowering effect of terlipressin in decompensated cirrhosis: Comparison to the molecular adsorbent recirculating system and correlation with clinical status. Eur J Gastroenterol Hepatol 16: 1335-1338, 2004.
18. Laleman W, Wilmer A, Evenepoel P, et al.: Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 10: R108, 2006.
19. Stange J, Mitzner S: A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 19: 677-691, 1996.
20. Stadlbauer V, Krisper P, Beuers U, et al.: Removal of bile acids by two different extracorporeal liver support systems in acute-onchronic liver failure. ASAIO J 53: 187-193, 2007.
21. Auth MK, Kim HS, Beste M, et al.: Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J Pediatr Gastroenterol Nutr 40: 54-59, 2005.
22. Isoniemi H, Koivusalo AM, Repo H, et al.: The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplant Proc 37: 1088-1090, 2005.
23. Di Campli C, Zocco MA, Gaspari R, et al.: The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 37: 2551-2553, 2005.
24. Ilonen I, Koivusalo AM, Hö ckerstedt K, Isoniemi H: Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 38: 3540-3543, 2006.
25. Stadlbauer V, Krisper P, Aigner R, et al.: Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 10: R169, 2006.
26. Klammt S, Mitzner S, Stange J, et al.: Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 19: 257-263, 2007.
27. Klammt S, Mitzner S, Stange J, et al.: Improvement of albumin binding capacity is associated with improved survival in patients with decompensated liver cirrhosis. Liver Transpl 14: 1333-1339, 2008.
28. Hetz H, Faybik P, Berlakovich G, et al.: Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: A pilot study. Liver Transpl 12: 1357-1364, 2006.
29. Schmidt LE, Wang LP, Hansen BA, Larsen FS: Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trial. Liver Transpl 9: 290-297, 2003.
30. Sen S, Mookerjee RP, Cheshire LM, et al.: Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 43: 142-148, 2005.
31. Mitzner S, Loock J, Peszynski P, et al.: Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS-A review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 17: 463-475, 2002.
32. Hassanein T, Tofteng F, Brown RS, et al.: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46: 1853-1862, 2007.
33. Camus C, Lavoué S, Gacouin A, et al.: Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 32: 1817-1825, 2006.
34. Sen S, Rose C, Ytrebø LM, et al.: Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: A randomized study. Crit Care Med 34: 158-164, 2006. (Pubitemid 43032393)
35. Mitzner SR: Drain the brain: Albumin dialysis for intracranial hypertension. Crit Care Med 34: 254-255, 2006.
36. Saich R, Collins P, Ala A, et al.: Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 17: 585-588, 2005.
37. Mitzner SR, Stange J, Klammt S, et al.: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277-286, 2000.
38. Ca'rdenas A, Ginès P: Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol 3: 338-348, 2006.
39. Moreau R, Lebrec D: Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 21: 111-123, 2007.
40. Wong F: Drug insight: The role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 4: 43-51, 2007.
41. Mitzner SR: Albumin dialysis: An update. Curr Opin Nephrol Hypertens 16: 589-595, 2007.
42. Koivusalo AM, Vakkuri A, Hö ckerstedt K, Isoniemi H: Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 37: 3315-3317, 2005.
43. Braun C, Birck R, Singer MV, et al.: Life-threatening intoxication with methylene bis(thiocyanate): Clinical picture and pitfalls. A case report. BMC Emerg Med 6: 5, 2006.
44. Liu YH, Wang Y, Yu LX, et al.: Artificial liver support molecular adsorbents recirculating system therapy as a bridge to retransplantation in two cases of long anhepatic duration. Hepatobiliary Pancreat Dis Int 3: 316-317, 2004.
45. Choi JY, Bae SH, Yoon SK, et al.: Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation-A pilot study. Liver Int 25: 740-745, 2005.
46. Doria C, Mandala' L, Scott VL, et al.: Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system: A single-center experience. Dig Dis Sci 51: 47-53, 2006.
47. Trittenwein G, Boigner H, Mostafa G, et al.: Bridging to transplantation in acute liver failure in a 7-month-old infant. Wien Klin Wochenschr 118: 298-301, 2006.
48. Wai CT, Lim SG, Aung MO, et al.: MARS: A futile tool in centres without active liver transplant support. Liver Int 27: 69-75, 2007.
49. Bellmann R, Graziadei IW, Feistritzer C, et al.: Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 10: 107-114, 2004. (Pubitemid 38885901)
50. Montero JL, Pozo JC, Barrera P, et al.: Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 38: 2511-2513, 2006.
51. Parés A, Cisneros L, Salmerón JM, et al.: Extracorporeal albumin dialysis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 99: 1105-1110, 2004.
52. Pichon N, François B, Chevreuil C, Gaulier JM: Albumin dialysis: A new therapeutic alternative for severe diltiazem intoxication. Clin Toxicol (Phila) 44: 195-196, 2006.
53. Lee KH, Lee MK, Sutedja DS, Lim SG: Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 25: 973-977, 2005.
54. Lionte C, Sorodoc L, Simionescu V: Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with molecular adsorbent recirculating system (MARS). Rom J Gastroenterol 14: 267-271, 2005.
55. El Banayosy A, Kizner L, Schueler V, et al.: First use of the molecular adsorbent recirculating system technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 50: 332-337, 2004.
56. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C: Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: A systematic review. JAMA 289: 217-222, 2003.
57. Hessel FP, Mitzner SR, Rief J, et al.: Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 23: 66-72, 2003.
58. Hessel FP: Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Cost Eff Resour Alloc 4: 16, 2006.
59. Saliba F, Camus C, Durand F, et al.: Predictive factors of transplant Free survival in patients with Fulminant and Subfulminant Hepatic Failure: Results from a randomized controlled multicenter trial. J Hepatol 50 (Suppl. 1): S89-S90, 2009.
60. Faybik P, Bacher A, Kozek-Langenecker SA, et al.: Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: An observational study. Crit Care 10: R24, 2006.
61. Allen JW, Hassanein T, Bhatia SN: Advances in bioartificial liver devices. Hepatology 34: 447-455, 2001.
62. Stange J, Mitzner S: Cell sources for bioartificial liver support. Int J Artif Organs 19: 14-17, 1996.